

EXECUTIVE REPORT 2024



INCLIVA | VLC
Biomedical Research Institute

EXECUTIVE REPORT 2024



1. PRESENTATION

The Hospital Clínico Universitario of Valencia Research Foundation was established in the year 2000 as the first Valencian research foundation affiliated with a public hospital. Ten years later, various centres of excellence in biomedical research from the University of Valencia and Carlos Simón Foundation joined the Foundation signed specific agreements to join the foundation, and thus INCLIVA Biomedical Research Institute was formed.

INCLIVA's main aims are to manage the biomedical research carried out by the Hospital Clínico Universitario de Valencia and its Health Department, and to encourage teaching and scientific activities, thus improving patient treatment and knowledge sharing.

In 2011 INCLIVA was accredited as a Biomedical Research Institute by the Ministry of Science and Innovation (Ministerio de Ciencia e Innovación), thus obtaining preferential treatment from the Carlos III Health Institute (Instituto de Salud Carlos III) in recognition of its excellence in research.

INCLIVA's accreditation as Health Research Institute was officially renewed for five years in 2021.

2. STRUCTURE OF IIS INCLIVA

INCLIVA Biomedical Research Institute (IIS INCLIVA) conducts research in four R&I areas organized into 58 research groups, of which 10 are emerging and 8 are associated clinical groups. All the groups develop their scientific activity with a common goal: to respond to healthcare needs and improve the R&D&i system.



Mission

To offer solutions to public health issues via scientific activity of the highest quality applied to healthcare.

Vision

To establish our institute as a centre of scientific excellence by developing research that maximizes existing resources and capabilities, increasing quality and societal impact.

Values

Citizen-oriented and committed to society: to find solutions to society's main health challenges while committing to transparency, respect for the environment and sustainability.

Excellence: a permanent focus on scientific and management excellence.

Support for professionals: equal opportunities, attracting young talent and retaining established talent.

Transparency: all work carried out at every level must be transmitted to all the institution's professionals, who must be aware of the processes, decisions and results obtained.

Partnerships and collaboration: successful scientific activity depends on strengthening collaborative ties, both internally and externally, to improve the quality and impact of the results.

Transversal scientific programmes

In line with its commitment to promoting collaborative and multidisciplinary research, INCLIVA has established a structure organized around seven scientific programmes focused on specific diseases from a translational perspective:

Programme in Overweight and Cardiovascular and Renal Risk

Programme in Detection and Control of Ventricular Dysfunction

Programme in Rare Diseases

Programme in Neurological Impairment

Program in Translational Oncology

Programme in Reproductive Medicine

Programme in Aging and Associated Diseases

Cardiovascular area



Coordinator:
Mr. Francisco Javier Chorro

Mission: to contribute to the understanding of different aspects of cardiovascular disease (CVD) from its origins to its consequences.

13 research groups

- Research Group on Cardiometabolic Risk and Diabetes
José Tomás Real Collado
Sergio Martínez Hervás
- Genomics and Diabetes Unit
Felipe Javier Chaves Martínez
- Research Group on Cardiac Experimental Electrophysiology
Francisco Javier Chorro Gascó
Antonio M. Alberola Aguilar
- Research Group on Endothelial Cells (LINCE)
Susana Novella del Campo
Carlos Hermenegildo Caudevilla
- Research Group on Clinical Cardiology
Juan Sanchis Forés
- Research Group for the Prevention of Cardiovascular Risk in Children and Adolescents
Empar Lurbe i Ferrer

- Cardiometabolic Research Group on Primary Care
Jorge Navarro Pérez
- Research Group on the Study of Cardiometabolic and Renal Risk
Josep Redón i Mas
Raquel Cortés Vergaz
- Research Group on Vascular Function
José M^a Vila Salinas
M^a Dolores Mauricio Aviñó
- Research Group on Pediatric Nutrition
Cecilia Martínez Costa
- Group on Translational Research in Ischemic Heart Disease
Vicente Bodí Peris
- Research Group on Heart Failure
Julio Núñez Villota
- Research Group on Renal Disease
Jose Luis Górriz Teruel

Number of publications

209

Average IF

6.4125

Number of research projects

57

Oncology area



Coordinator:
Mr. Andrés Cervantes

Mission: to contribute to the understanding of different aspects of oncological diseases, in terms of diagnosis, molecular characterization and selecting specific molecular targets of therapeutic interest.

12 research groups

- Research Group on Histopathology and Tissue Engineering
Manuel Mata Roig
- Research Group on Central Nervous System Tumours
Miguel Cerdá Nicolás
- Research Group of Innovative Diagnostic and Therapeutic Developments in Solid Tumours – InDeST
Andrés Cervantes Ruipérez
- Research Group on Breast Cancer Biology
Ana Lluch Hernández
Pilar Eroles Asensio
- Research Group on Skin Cancer
José Carlos Monteagudo Castro

- Translational Research Group on Pediatric Solid Tumors
Samuel Navarro Fos
Rosa Noguera Salvá
- Research Group on Hematopoietic Transplantation
Carlos Solano Vercet
- Research Group on Lymphoproliferative Disorders
M^a José Terol Casterá
- Research Group on Myeloid Neoplasms
Mar Tormo Díaz
- Research Group on Molecular Imaging and Metabolomics
Daniel Monleón Salvadó
- Research Group on Molecular Microbiology and Microbial Pathogenesis
David Navarro Ortega

Emerging group

- Translational Research Group on Esophagogastric Cancer
Tania Carolina Fleitas Kanonnikoff

Number of publications

238

Average IF

7.738

Number of research projects

73

Metabolism and Organic Damage area



Coordinator:
Mr. José Viña

Mission: to contribute to the understanding of the etiology, pathophysiology and diagnosis mechanisms and treatment of various metabolic diseases and those triggering organ damage.

21 research groups

- Research Group on Genetics of Osteoporosis
Miguel Ángel García Pérez
- Research Group on Neurological Impairment
Carmina Montoliu Félix
- Research Group on Inflammation
María Jesús Sanz Ferrando
- Research Group on Psychiatry and Neurodegenerative Diseases
Juan Nacher Roselló
- Research Group on Respiratory Diseases
Jaime Signes-Costa Miñana
- Research Group on Tissular Biochemistry
Juan R. Viña Ribes
- Research Group on Aging and Physical Activity
José Viña Ribes
- Research Group on Anaesthesiology and Reanimation
Rafael Badenes Quiles
- Research Group on Human Translational Genomics
Rubén D. Artero Allepuz
- Research Group on General and Digestive Surgery
Luis Sabater Ortí
- Research Group on Personal Autonomy, Dependence and Severe Mental Disorders (TMAP)
Rafael Tabarés Seisdedos
- Research Group on Cellular and Organic Physiopathology of Oxidative Stress
Federico V. Pallardó Calatayud
- Research Group on Healthy Aging (MiniAging)
Consuelo Borrás Blasco
- Research Group on Exercise, Nutrition and Healthy Lifestyle
Mª Carmen Gómez Cabrera
- Research Group on Genetics and Biomarkers of Rare Diseases
Carmen Espinós Armero

Emerging groups

- Research Group on Inflammation: Metabolism and Organic Damage Line
Laura Piqueras Ruiz
- Research group on Metabolic Diseases
Herminia González Navarro
- Research Group on Rare Respiratory Diseases (RRD)
Francisco Dasí Fernández
- Research Group on Epigenomics and Translational Epigenetics
José Luis García Giménez
- Research Group in Medical Chemistry for Drug Development
Nuria Cabedo Escrig
- Research Group on Neurobiology and Molecular Physiopathology in Rare Diseases – NeuroFisER
Pilar González Cabo

Number of publications	Average IF	Number of research projects
261	6.8841	119

Reproductive Medicine area



Coordinator:
Mr. Carlos Simón


Mission: to advance the understanding of human reproduction for translational application, improving the efficiency of assisted reproduction treatment and reducing adverse effects.

5 research groups

- Research Group on Women's Health
Antonio Cano Sánchez
- Research Group on Reproductive Medicine
Carlos Simón Vallés

Emerging groups


- Research Group on Therapies Against Endometriosis and Endometrial Cancer
Raúl Gómez Gallego
- Research Group on Maternal Foetal Communication
Felip Vilella Mitjana
- Research Group on Molecular Diagnosis of Gynaecological Tumours
Aymara Mas Perucho



Associated Clinical Groups area


8 research groups

- Research Group on Research in Care. INVESTENF-INCLIVA
Cintia Borja Herrero
- Associated Clinical Group in Urology
José Martínez Jabaloyas
- Associated Clinical Group in Digestive Medicine
Isabel Pascual Moreno
- Associated Clinical Group in Otorhinolaryngology
Jaime Marco Algarra
- Associated Clinical Group in Traumatology and Orthopedics
Antonio Silvestre Muñoz
- Associated Clinical Group in Neurology
José Miguel Láinez Andrés
- Associated Clinical Group in Pharmacy
Manuel Alós Almiñana
- Clinical Associated Group in Nuclear Medicine
Rafael Díaz Expósito



3. SCIENTIFIC OUTPUT

Indexed publications




The number of publications in 2024 was 697, with a cumulative impact factor of 5.744,11 translating into an average impact factor of 8.2412.


Publications	Cumulative Impact Factor	Average Impact Factor
697	5.744,11	8.2412

Quartile distribution

Approximately 91% of the papers published in indexed journals last year belong to the first and second quartiles of their corresponding thematic categories:



Doctoral theses defended




4. SCIENTIFIC ACTIVITY

Research projects


In 2024, 194 projects (178 national and 16 international) were active in competitive bidding, of which 50 new competitive projects were awarded (45 national and 5 international).

Active Projects each year



Clinical trials and other studies


As a result of its activity in 2024, INCLIVA managed a total of 189 studies (clinical trials and observational studies).



Evolution of clinical trial distributed by phase

During the period 2020–2024, INCLIVA prioritised Phase I and Phase II trials, fulfilling its objective of developing clinical research in its initial phases and thus contributing to translational research that moves scientific knowledge from bench to bedside.

Evolution of clinical trial distributed by phase




Phase I oncology clinical trials

INCLIVA is the only hospital in Valencia and one of only a few in Spain performing Phase I cancer clinical trials, in which a substance or product is tested on humans for the first time.

In 2024, 240 ongoing clinical trials were conducted in the INCLIVA Oncology Department, 162 of which were related to treatment in the early stages of testing: 92 in Phase I (first in humans) and 70 in Phase II.

The following graph shows the number of Phase I oncology clinical trials during the last five years.




Research promotion initiatives

INCLIVA funded 25 grants in centres of excellence during 2024 to help researchers acquire new knowledge for clinical and research techniques.

In addition, four IIS INCLIVA researchers carried out internships in external centres and eight others have been granted scholarships in IIS INCLIVA.

A total of 114 students enrolled in Vocational Training, Bachelor's or Master's degree programs were accepted for training internships in different research groups in INCLIVA during 2024.




5. KNOWLEDGE TRANSFER ACTIVITIES

As part of its organizational mission, INCLIVA Biomedical Research Institute is fully committed to transferring knowledge to both the National Health System and the industrial sector.

Knowledge transfer to the National Health System

Clinical guidelines and consensus documents are one of the best indicators of knowledge transfer from research to clinical practice. The number of guidelines with INCLIVA-affiliated author participation published in indexed journals in 2024 is shown below.



Innovation and knowledge transfer

INCLIVA's Innovation Unit supports INCLIVA professionals in developing translational research with greater societal impact, promotes innovation and collaboration with other research centres and industrial partners, and assesses the viability of innovative ideas at different stages to ensure that only the best ideas are launched on the market.



6. NETWORKS AND PLATFORMS

Cooperative research networks

Carlos III Health Institute supports the creation of stable research network structures such as CIBER (Network of Centres for Biomedical Research). INCLIVA participates in this research structure through its associated groups.

Research Area	INCLIVA PI	Scientific Network	Reference
Cardiovascular	Mr. José Tomás Real Collado	<i>ciber</i> DEM	CB07/08/0018
	Mrs. Empar Lurbe i Ferrer	<i>ciber</i> OBN	CB06/03/0039
	Mr. Vicent Bodí Peris	<i>ciber</i> CV	CB16/11/00486
	Mr. Juan Sanchis Forés	<i>ciber</i> CV	CB16/11/00420
Metabolism and Organ Damage	Mr. Federico V. Pallardó Calatayud	<i>ciber</i> ER	CB06/07/0073
	Mr. Ruben Artero Allepuz	<i>ciber</i> ER	CB23/07/00005
	Mr. Juan Nacher Roselló	<i>ciber</i> SAM	CB07/09/006
	Mr. Rafael Tabarés Seisdedos	<i>ciber</i> SAM	CB07/09/0021
	Mr. José Viña Ribes	<i>ciber</i> FES	CB16/10/00435
Oncology	Mr. Andrés Cervantes Ruipérez	<i>ciber</i> ONC	CB16/12/00473
	Mrs. Rosa Noguera Salvá	<i>ciber</i> ONC	CB16/12/00484

Associated networks and platforms

National



International



7. HUMAN RESOURCES AT INCLIVA FROM A GENDER PERSPECTIVE

HR Excellence in Research


In 2019, IIS INCLIVA obtained the HR Excellence in Research (HRS4R) quality seal, which recognizes the ability to attract talent, generate a favourable work environment, promote research and innovation, and enhance the careers of researchers within the European framework.



HR EXCELLENCE IN RESEARCH

Breakdown of research group staff


A total of 764 researchers belong to consolidated, emerging and associated research groups, with the following EURAXESS profile distribution.



Women and men working together at INCLIVA

As part of its commitment towards guaranteeing real equality between women and men, INCLIVA's Board of Trustees approved the II INCLIVA Equality Plan (2020-2024) following approval by the Equality Committee.


In 2024, a total of 289 employees joined INCLIVA, of whom 71% are women. The percentage of women hired has increased year on year for the last three years.



8. FINANCIAL RESOURCES


INCLIVA funding

INCLIVA received a total of €24,261,047 in funding in 2024



Funding Sources in 2024

These funds come from competitive sources and grants, private funding sources and donations.




9. COMMUNICATION





Press office

During 2024, INCLIVA posted a total of 122 press releases on the website.

Press releases on web



Social media users 2024

			
Facebook	X	LinkedIn	Instagram
7,461	6,409	20,581	2,917

Facebook: <https://www.facebook.com/INCLIVA>
X: https://twitter.com/incliva_iis
LinkedIn: <https://www.linkedin.com/company/incliva-instituto-de-investigación-sanitaria>
Instagram: <https://www.instagram.com/iisincliva>

INCLIVA Website 2024



Website users	Website sessions	Website new sessions
139,769	270,595	132,931

Outreach 2024

News pieces on the INCLIVA website	News pieces on the radio	News pieces on TV
122	17	18

INCLIVA | VLC

Biomedical Research Institute

Avda. Menéndez Pelayo, 4 accesorio.

46010 Valencia. España

T. 34 96 197 35 17

F. 34 96 197 35 40

www.incliva.es

incliva@incliva.es